The global market for Kaposi sarcoma is highly consolidated in nature with two players holding a massive share of the market, states a new market intelligence study that’s has been recently published by Transparency Market Research. In 2015, the two leading players, namely Merck & Co. Inc. and Johnson & Johnson held a share of around 50% of the global market and is projected to remain in the similar situation in the next few years. The rising research and development activities in this field and the technological advancements are some of the major factors that are anticipated to enhance the growth of the global Kaposi sarcoma market in the coming few years. In addition to this, the increasing mergers and acquisitions and strategic collaboration is further anticipated to accelerate the growth of the overall market in the next few years.
According to the market intelligence study by Transparency Market Research, in 2015, the global market for Kaposi sarcoma was worth US$118.5 mn and is anticipated to reach a value of US$143.2 mn by the end of 2024. The market is predicted to register a steady 2.20% CAGR between 2016 and 2024.
Presence of Leading Players to Drive North America Kaposi Sarcoma Market
The global market for Kaposi sarcoma has been categorized on the basis of geography into Latin America, North America, Europe, Asia Pacific, and the Middle East and Africa. Among these, North America led the global market in the last few years and is likely to remain in the similar position in the coming few years. The presence of a large number of leading players and the increasing costs of drugs are some of the major factors that are estimated to enhance the growth of the North America market in the next few years. In addition to this, the easy availability of advanced drugs and the technologically advanced healthcare are some of the other factors that are predicted to enhance the growth of the market in the near future. Furthermore, the Middle East and Africa is estimated to witness a healthy growth in the near future.
The global Kaposi sarcoma market has been categorized on the basis of treatments into chemotherapy, immunotherapy, and antiretroviral therapy. Among these, the antiretroviral therapy segment is expected to account for a major share of the overall market in the next few years. The rising incidence rate of AIDS-associated Kaposi sarcoma is one of the key factors predicted to enhance the growth of the market in the coming few years. Furthermore, the rising preference for this treatment and the high cost of treatment are some of the other factors that are predicted to enhance the growth of this segment in the next few years.
Rising Cases of Cancer to Encourage Growth of Kaposi Sarcoma Market
The increasing procedures for organ transplants and the rising incidence of cancer are the key factors that are projected to encourage the growth of the global Kaposi sarcoma market in the next few years. Furthermore, the rising cases of HIV/AIDS related to Kaposi sarcoma is another key factor, which is likely to accelerate the growth of the overall market in the next few years. In addition to this, the technological advancements in the healthcare sector and the introduction of new drugs for Kaposi sarcoma are projected to enhance the growth of the Kaposi sarcoma market in the next few years.
This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Kaposi Sarcoma Market (Treatment – Chemotherapy (Liposomal Anthracyclines, Alkaloids), Immunotherapy, HAART); Distribution Channel – Hospitals, Cancer Research Institutes, Multispecialty Clinics,Ambulatory Surgical Centers) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
- The rising incidence of cancer is one of the key factors encouraging the growth of the Kaposi sarcoma market in the next few years.
- The rising level of competition and the increasing focus on development of new products are predicted to enhance the growth of the market in the near future.
The global Kaposi sarcoma market has been segmented as below:
- Kaposi Sarcoma Market, By Type of Treatment
- Liposomal Anthracyclines
- Kaposi Sarcoma Market, By Distribution Channel
- Cancer Research Institutes
- Multispecialty Clinics
- Ambulatory Surgical Centers
- Kaposi Sarcoma Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South African Republic
- Rest of Middle East and Africa
- North America
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
7 of 10 large enterprizes view our ToC to take the right decision.View Report ToC